72. Remdesivir vs Standard Care in Patients with Moderate covid-19

BACKGROUND: Remdesivir (RDV) shortens time to recovery time in patients with severe COVID-19. Its effect in patients with moderate COVID-19 remains unclear. METHODS: We conducted an open-label, phase 3 trial (NCT04252664) involving hospitalized patients with confirmed SARS-CoV-2 infection, evidence...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Marty, Francisco M, Malhotra, Prashant, Gottlieb, Robert L, Tashima, Karen T, Galli, Massimo, Chai, Louis Yi Ann, SenGupta, Devi, Hyland, Robert H, Wang, Hongyuan, Zhong, Lijie, Cao, Huyen, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Brown, Michael, Goikoetxea, Ane Josune, Jain, Mamta, Hui, David Shu Cheong, Bernasconi, Enos, Spinner, Christoph
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Poster Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777983/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.382
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars